5/15
04:09 pm
ka
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities [Yahoo! Finance]
High
Report
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities [Yahoo! Finance]
5/15
04:01 pm
ka
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
Low
Report
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
4/8
04:01 pm
ka
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
High
Report
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
3/21
04:14 pm
ka
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/21
04:02 pm
ka
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
Medium
Report
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
3/12
08:17 am
ka
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported [Yahoo! Finance]
High
Report
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported [Yahoo! Finance]
3/12
08:00 am
ka
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
High
Report
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
2/29
08:30 am
ka
Kineta Announces Restructuring and Exploration of Strategic Alternatives
High
Report
Kineta Announces Restructuring and Exploration of Strategic Alternatives
2/22
08:30 am
ka
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
Low
Report
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium